Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Letters to the Editor

Prostate cancer screening

Sherry Zhang, MD and Ian Jenkins, MD
Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: https://doi.org/10.3949/ccjm.88c.05001
Sherry Zhang
University of California, San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Jenkins
University of California, San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editor: We read with interest the article about prostate specific antigen (PSA) and screening, “Prostate cancer screening and the role of PSA: A UK perspective” by Sooriakumaran in the January 2021 issue.1 We are concerned with the author’s endorsement of unproven management options, an unreferenced claim that transperineal prostate biopsies curtail antibiotic resistance, and especially the generalized take-home point that “PSA screening saves lives.”

The European Randomised Study of Screening for Prostate Cancer (ERSPC), which the author used to justify screening, showed no such benefit. The relative risk for all-cause mortality was 1.00 (95% confidence interval 0.98–1.02, P = .82).2 Only a disease-specific benefit was detected: 570 men would need to be screened to prevent 1 death of prostate cancer at 16 years in the latest follow-up of the study.3 For this marginal benefit, substantial costs are incurred. These include the psychological consequences of a cancer diagnosis, harms of prostate biopsies, and side effects of treatments including radiation, radical prostatectomy, and androgen deprivation therapy (eg, impotence or incontinence, or both). The US Preventive Services Task Force estimates that for 1,000 men ages 55 to 69 who are screened, 240 will experience the stress of an elevated PSA, 100 will be diagnosed with cancer, and at least 60 will suffer serious harm.4

Causing this harm is not inexpensive. A cascade of testing and procedures follows an elevated PSA, which by itself costs about $40. However, additional fees can quickly add up—that of ultrasounds ($150), specialist consultations ($350), prostate biopsies ($500), and more.5 The United States wastes billions of dollars annually on nonbeneficial healthcare costs. We believe that higher value care is crucial for patient outcomes and for the sustainability of healthcare spending. The costs of PSA testing—both financial and to the patient’s well-being—are not worth it.

  • Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Sooriakumaran P
    . Prostate cancer screening and the role of PSA: A UK perspective. Cleve Clin J Med 2021; 88(1)14–16. doi:10.3949/ccjm.88a.20164
    OpenUrlFREE Full Text
  2. ↵
    1. Schröder FH,
    2. Hugosson J,
    3. Roobol MJ, et al
    . Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384(9959):2027–2035. doi:10.1016/S0140-6736(14)60525-0
    OpenUrlCrossRefPubMed
  3. ↵
    1. Hugosson J,
    2. Roobol MJ,
    3. Månsson M, et al
    . A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol 2019; 76(1):43–51. doi:10.1016/j.eururo.2019.02.009
    OpenUrlCrossRefPubMed
  4. ↵
    1. US Preventive Services Task Force;
    2. Grossman DC,
    3. Curry SJ,
    4. Owens DK, et al
    . Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018; 319(18):1901–1913. doi:10.1001/jama.2018.3710
    OpenUrlCrossRefPubMed
  5. ↵
    1. American Academy of Family Physicians
    . The PSA blood test for prostate cancer. When men need it—and when they don’t. Choosing Wisely April, 2014. Accessed March 11, 2021. https://www.choosingwisely.org/patient-resources/psa-test-for-prostate-cancer/
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 88 (5)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 5
1 May 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prostate cancer screening
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prostate cancer screening
Sherry Zhang, Ian Jenkins
Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: 10.3949/ccjm.88c.05001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prostate cancer screening
Sherry Zhang, Ian Jenkins
Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: 10.3949/ccjm.88c.05001
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Antiobesity drug therapy
  • Physician resistance to obesity pharmacotherapy
  • In Reply: Physician resistance to obesity pharmacotherapy
Show more Letters to the Editor

Similar Articles

Subjects

  • Preventive Care
  • Oncology
  • Men's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire